24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Diabetes
Resources
Basic InformationLatest News
Diabetes Tougher on Women's HeartsDiabetes Technology Often Priced Out of ReachSupplements Don't Prevent Kidney Disease in Type 2 DiabeticsWhy Are Insulin Prices Still So High for U.S. Patients?Health Tip: Snacks for People With DiabetesHigh-Tech Pacifier Might Monitor Baby's Blood SugarThe Exercise Effect and PrediabetesNext-Gen Artificial Pancreas Boosts Blood Sugar ControlHurricanes Raise Death Risk for Older Diabetics, Even Years LaterYou've Lost the Weight -- Now Keep It Off to Keep Diabetes at BayCould a Pill Replace Insulin Shots?High-Fiber Diet Tied to Lower Heart Risk in Diabetes PatientsJust a Little Weight Loss Can Put Diabetes Into RemissionAffordable Care Act Insured Millions of Uninsured DiabeticsOlder Diabetics May Be Getting Too Much InsulinIt Takes Less Weight to Trigger Diabetes in Minorities Than WhitesFDA OKs New Pill for Type 2 DiabetesAHA News: These Diets Helped Women With Diabetes Cut Heart Attack, Stroke RiskKeeping Blood Sugar Steady Helps You Live Longer With DiabetesAre Shorter Folks at Higher Risk for Type 2 Diabetes?Diabetes Control Has Stalled Across U.S.Fish Oil Not a Magic Pill Against DiabetesAsian Study Finds Diabetes, Heart Failure a Dangerous DuoCaring Doctors Can Be Life-Changing for Diabetic PatientsKeto Diet May Help Control Type 2 DiabetesHealth Tip: Living With HypoglycemiaHealth Tip: Understanding PrediabetesFDA Approves First Needle-Free 'Rescue' Drug for Low Blood Sugar EpisodesDiabetes Raises Heart Failure Risk More in Women Than MenCan You Live Well With Type 1 Diabetes for 81 Years? Just Ask Don RayEasing Depression Can Bring Longer Life to People With DiabetesMedtronic Recalls Some Insulin Pumps as FDA Warns They Could Be HackedFDA Approves Victoza Injection for Children 10 Years and OlderCommon Infant Vaccine May Also Shield Kids From Type 1 DiabetesType 1 Diabetes Might Affect Young Kids' Brain DevelopmentDrug May Help Delay Onset of Type 1 DiabetesVitamin D Supplements Don't Prevent Type 2 Diabetes: StudyWhat and How You Eat Affects Your Odds for Type 2 DiabetesAHA News: Diabetes and Heart Failure Are Linked; Treatment Should Be TooMidlife Diabetes Can Really Raise Your Odds for Stroke Years LaterTight Diabetes Control Alone May Not Benefit the Heart Long-TermOpen Communication Helps Teens Manage Type 1 DiabetesNew Gene Variants for Type 2 Diabetes FoundPost-Hospital Low Blood Sugar a Danger to DiabeticsAHA News: Why Are Women With Diabetes at Greater Risk for Poor Heart Health?Newer Diabetes Drugs Linked to 'Flesh-Eating' Genital InfectionAHA News: Study Backs Lower Blood Pressure Target for People With DiabetesNewer Diabetes Drug Shows Promise in Kids, TeensNo 'One-Size-Fits-All' Diet for Diabetics, Expert Panel SaysMicrobes in Diabetic Foot Ulcers May Help Predict Treatment Success
Links
Related Topics

Medical Disorders

FDA OKs New Pill for Type 2 Diabetes

HealthDay News
by -- Steven Reinberg
Updated: Sep 20th 2019

new article illustration

FRIDAY, Sept. 20, 2019 (HealthDay News) -- A new pill to lower blood sugar for people with type 2 diabetes was approved by the U.S. Food and Drug Administration on Friday.

The drug, Rybelsus (semaglutide) is the first pill in a class of drugs called glucagon-like peptide (GLP-1) approved for use in the United States. Before Rybelsus, the drug had to be injected.

"Before this approval, patients did not have an oral GLP-1 option to treat their type 2 diabetes, and now patients will have a new option for treating type 2 diabetes without injections," said Dr. Lisa Yanoff in an agency news release. She is acting director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research.

GLP-1 is a hormone often found in low levels in people with type 2 diabetes. Rybelsus acts by slowing digestion and preventing the liver from making too much sugar, which helps the pancreas produce more insulin.

In clinical trials, Rybelsus significantly lowered blood sugar.

After 26 weeks, 77% of patients taking 14 mg of Rybelsus daily saw their HbA1C drop below 7% compared with 31% among those receiving a placebo. HbA1C is a measure of blood sugar.

Rybelsus, made by the pharmaceutical company Novo Nordisk, is not recommended as the first choice for treating diabetes, the FDA said.

The drug has potential risks. It may cause certain thyroid tumors. Patients who have had thyroid cancer or have a relative who has had it are advised not to take Rybelsus.

Rybelsus is also not for people with type 1 diabetes or diabetic ketoacidosis. The drug label also warns about inflammation of the pancreas, vision loss, low blood sugar and kidney injury.

The most common side effects are nausea, diarrhea, vomiting, decreased appetite, indigestion and constipation, the FDA noted.

More information

For more on type 2 diabetes, see the American Diabetes Association.